Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

September 18, 2007 12:15 ET

Ambrilia Presents Latest Data on its Novel HIV Integrase Inhibitors at the 47th ICAAC

MONTREAL, QUEBEC--(Marketwire - Sept. 18, 2007) - Ambrilia Biopharma Inc. (TSX:AMB) presented today new data on its novel series of HIV integrase inhibitors (pyrazolopyridine inhibitors), showing their potential synergies with some of the known integrase inhibitors (diketo acid inhibitors) currently in clinical development. Furthermore, Ambrilia's pyrazolopyridine inhibitors bind to a different site on the HIV integrase enzyme from that of the known competitive active site inhibitors such as the diketo acid derivatives, suggesting a different mechanism of strand transfer inhibition. The poster entitled "Pyrazolopyridine Compounds as Novel HIV-1 Integrase Inhibitors" was presented by Dr. Jinzi Wu, Vice-President, Preclinical and Basic Research, Ambrilia, at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy ("ICAAC") held in Chicago (September 17-20).

"The observation of synergies against enzymatic activities of HIV-1 integrase, when combining Ambrilia's compounds with some of the clinical stage integrase inhibitors, is quite appealing. This could be due to the distinct mechanism of action of our compounds, and will potentially allow them to broaden the therapeutic options available, and possibly to remain active if the virus develops resistance to the currently known products", said Dr. Bonabes de Rouge, Senior Executive Vice-President and Chief Scientific Officer of Ambrilia.

HIV INTEGRASE INHIBITORS PRESENTATION SUMMARY

The poster presents a novel series of pyrazolopyridine integrase inhibitors developed by Ambrilia. A number of compounds demonstrated potent inhibition of integrase strand transfer activity. Inhibitor cross-competition studies showed that the pyrazolopyridine inhibitors bind to a different site on the integrase enzyme from that of known active site competitive strand transfer inhibitors, such as diketo acid compounds, indicating a potentially distinct mechanism of strand transfer inhibition. This could lead to a different resistance profile than that of the known diketo acid inhibitors in clinical development. Furthermore, the findings suggest that these novel pyrazolopyridine integrase inhibitors bind to a site on the integrase enzyme similar to that for pyridoxal-5'-phosphate, a known C-terminal domain binding inhibitor of integrase. Finally, drug combinations studies performed with some diketo acid inhibitors suggest that there are potential synergies of inhibiting integrase enzymatic activities when pyrazolopyridine and diketo acids inhibitors are combined.

The poster is available on Ambrilia's web site at: www.ambrilia.com, Product Pipeline section, Scientific library, HIV/AIDS integrase inhibitor program.

Ambrilia's forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's Management's Discussion & Analysis of Financial Condition and Results of Operations which contain a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements.

ABOUT THE 47TH ICAAC

Held annually in the fall, the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the world's premier meeting on infectious diseases and antimicrobial agents, organized by the American Society for Microbiology. More than 12,000 scientists from around the world participate in ICAAC to exchange information and foster global solutions to the challenges of HIV/AIDS, anthrax, smallpox, SARS, and other topics including bioterrorism preparedness, recognition, detections, and medical treatments. www.icaac.org

ABOUT HIV INTEGRASE INHIBITORS

Integrase inhibitors emerge as a promising new class of drugs in the arsenal against HIV/AIDS. They disrupt the viral cycle by targeting the integrase enzyme, preventing viral DNA strand insertion into the infected cell for replication. The compounds currently being developed by some pharmaceutical companies are diketo acid derivative based which act as competitive strand transfer inhibitors. While these compounds should prove to be highly effective and relatively safe HIV medicines, viral resistance and cross-resistance has emerged rapidly in clinical trials. These limitations call for the development of novel integrase inhibitors with a distinct mechanism of action which may lead to a different resistance profile from known competitive strand transfer inhibitors.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia's product portfolio includes an HIV protease inhibitor program (with lead compound PPL-100), an HIV integrase inhibitor program, two new formulations of existing peptides (Octreotide and Goserelin), other tumor targeted peptides such as PCK3145 and the Tumor and tumor Vasculature Targeting (TVT) technology platform, as well as other anti-viral programs. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

Contact Information